Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome.

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Giuseppe PattiNiccolò Marchionni

Abstract

Despite recent achievements in secondary cardiovascular prevention, the risk of further events in patients with chronic coronary syndromes (CCS) remains elevated. Highest risk is seen in patients with recurrent events, comorbidities or multisite atherosclerosis. Optimising antithrombotic strategies in this setting may significantly improve outcomes. The higher the baseline risk, the higher the absolute event reduction with approaches using combined antithrombotic treatments. Tailoring such strategies to the individual patient risk appears crucial to achieve net benefit (i.e., substantial ischaemic event prevention at a limited cost in terms of bleeding). This paper focuses on antithrombotic and non-pharmacological approaches to secondary cardiovascular disease prevention in CCS. In particular, we critically review current evidence on the use of dual antithrombotic therapy, including the newest approach of aspirin plus low-dose anticoagulation and its net clinical outcome according to baseline risk.

References

Aug 11, 2000·JAMA : the Journal of the American Medical Association·E M AntmanE Braunwald
Oct 29, 2003·Archives of Internal Medicine·Christopher B GrangerUNKNOWN Global Registry of Acute Coronary Events Investigators
Apr 22, 2005·Journal of Thrombosis and Haemostasis : JTH·S SchulmanUNKNOWN Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on T
Jan 16, 2007·Journal of Vascular Surgery·L NorgrenUNKNOWN TASC II Working Group
Mar 22, 2007·JAMA : the Journal of the American Medical Association·Ph Gabriel StegUNKNOWN REACH Registry Investigators
May 15, 2007·Journal of the American College of Cardiology·Deepak L BhattUNKNOWN CHARISMA Investigators
Aug 21, 2008·European Heart Journal·Andrzej BudajUNKNOWN OASIS 5 Investigators
Apr 30, 2010·Arquivos brasileiros de cardiologia·Luis C L CorreiaJosé Péricles Esteves
Jun 2, 2010·Journal of the American College of Cardiology·Roxana MehranGregg W Stone
Jan 21, 2011·The New England Journal of Medicine·Gregg W StoneUNKNOWN PROSPECT Investigators
Nov 21, 2013·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN ENGAGE AF-TIMI 48 Investigators
Nov 18, 2014·The New England Journal of Medicine·Laura MauriUNKNOWN DAPT Study Investigators
Mar 17, 2015·The New England Journal of Medicine·Marc P BonacaUNKNOWN PEGASUS-TIMI 54 Steering Committee and Investigators
Mar 20, 2015·Journal of the American College of Cardiology·Robert W YehUNKNOWN DAPT Study Investigators
Mar 30, 2016·JAMA : the Journal of the American Medical Association·Robert W YehUNKNOWN DAPT Study Investigators
Apr 6, 2016·Journal of the American College of Cardiology·Deepak L BhattPh Gabriel Steg
Apr 6, 2016·Journal of the American College of Cardiology·Marc P BonacaMarc S Sabatine
Aug 20, 2016·Journal of the American College of Cardiology·Sameer BansilalValentin Fuster
Dec 10, 2016·Journal of the American College of Cardiology·Antonio Gómez-OutesEmilio Vargas-Castrillón
Jun 18, 2017·European Journal of Preventive Cardiology·François SchieleRomain Chopard
Aug 29, 2017·The New England Journal of Medicine·John W EikelboomUNKNOWN COMPASS Investigators
Sep 9, 2017·Journal of the American College of Cardiology·Marc P BonacaMarc S Sabatine
Feb 7, 2018·Journal of the American College of Cardiology·Sameer BansilalA J Oude Ophuis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.